Signpath Pharma 10-K 9 Apr 15 2014 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Dec. 31, 2014	Mar. 31, 2015	Jun. 30, 2014
Document and Entity Information
Entity Registrant Name	SIGNPATH PHARMA, INC.
Document Type	10-K
Document Period End Date	31-Dec-14
Amendment Flag	FALSE
Entity Central Index Key	1455694
Current Fiscal Year End Date	-19
Entity Common Stock, Shares Outstanding		14,163,887
Entity Filer Category	Smaller Reporting Company
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	FY
Entity Public Float			$0
Entity Incorporation, State Country Name	Delaware
Entity Incorporation, Date of Incorporation	15-May-06

Balance_Sheets

Balance Sheets (USD $)	Dec. 31, 2014	Dec. 31, 2013
CURRENT ASSETS
Cash	$716,193	$1,241,397
Total Current Assets	716,193	1,241,397
TOTAL ASSETS	716,193	1,241,397
CURRENT LIABILITIES
Accounts payable and accrued expenses	447,999	421,632
Total Current Liabilities	447,999	421,632
STOCKHOLDERS' EQUITY
Common stock; $0.001 par value, 50,000,000 shares authorized; 14,123,887 and 12,877,500 shares issued and outstanding, respectively	14,124	12,879
Accrued dividends	969,230	1,353,961
Additional paid-in capital	12,700,365	10,120,454
Accumulated deficit	-13,416,598	-10,668,408
Total Stockholders' Equity	268,194	819,765
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	716,193	1,241,397
Series A Preferred Stock
STOCKHOLDERS' EQUITY
Preferred Stock	326	326
Series B Preferred Stock
STOCKHOLDERS' EQUITY
Preferred Stock	215	215
Series C Preferred Stock
STOCKHOLDERS' EQUITY
Preferred Stock	500	338
Series D Preferred Stock
STOCKHOLDERS' EQUITY
Preferred Stock	$32

Balance_Sheets_Parenthetical

Balance Sheets Parenthetical (USD $)	Dec. 31, 2014	Dec. 31, 2013
Common stock par value	$0.00	$0.00
Common stock shares authorized	50,000,000	50,000,000
Common stock shares issued	14,123,887	12,877,500
Common stock shares outstanding	14,123,887	12,877,500
Preferred Stock Par Value	$0.10
Preferred Stock Authorized	5,000,000
Series A Preferred Stock
Preferred Stock Par Value	$0.10	$0.10
Preferred Stock Authorized	5,000	5,000
Preferred Stock Issued	3,256	3,256
Preferred Stock Outstanding	3,256	3,256
Series B Preferred Stock
Preferred Stock Par Value	$0.10	$0.10
Preferred Stock Authorized	3,000	3,000
Preferred Stock Issued	2,146	2,146
Preferred Stock Outstanding	2,146	2,146
Series C Preferred Stock
Preferred Stock Par Value	$0.10	$0.10
Preferred Stock Authorized	6,000	6,000
Preferred Stock Issued	5,001	5,001
Preferred Stock Outstanding	3,380	3,380
Series D Preferred Stock
Preferred Stock Par Value	$0.10	$0.10
Preferred Stock Authorized	6,000	6,000
Preferred Stock Issued	320	320
Preferred Stock Outstanding

Statements_of_Operations

Statements of Operations (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Statements of Operations
REVENUES
OPERATING EXPENSES
General and administrative	73,005	53,957
Professional fees	413,953	808,865
Research and development	1,927,851	841,502
Salaries and wages	327,316	249,407
Total Operating Expenses	2,742,125	1,953,731
OPERATING LOSS	-2,742,125	-1,953,731
OTHER INCOME (EXPENSE)
Gain (loss) on derivative liability	0	-3,926
Transaction loss	-6,671
Interest income	606	785
Total Other Income (Expense)	-6,065	-3,141
NET LOSS BEFORE INCOME TAXES	-2,748,190	-1,956,872
Provision for income taxes
NET LOSS	-2,748,190	-1,956,872
DEEMED DIVIDEND ON WARRANTS		-2,445,621
PREFERRED STOCK DIVIDEND	-640,673	-492,089
NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS	($3,388,863)	($4,894,582)
BASIC AND DILUTED LOSS PER SHARE	($0.25)	($0.38)
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING	13,505,925	12,877,500

Statements_of_Stockholders_Equ

Statements of Stockholders' Equity (USD $)	Preferred Stock	Common Stock	Accrued Dividends	Additional Paid in Capital	Deficit Accumulated	Total
Balance at Dec. 31, 2012	$541	$12,839	$861,872	$1,286,613	($8,711,536)	($6,549,671)
Balance - shares at Dec. 31, 2012	5,402	12,837,500
Preferred stock issued for cash	338			3,379,662		3,380,000
Preferred stock issued for cash - shares	3,380
Stock offering costs				-550,326		-550,326
Common stock issued for services		40		33,960		-34,000
Common stock issued for services - shares		40,000
Executive forfeited salary				104,000		104,000
Amortization of options issued for services				667,449		667,449
Preferred dividend accrued			492,089	-492,089
Adjustment for derivative liability				5,691,185		5,691,185
Net loss					-1,956,872	-1,956,872
Balance at Dec. 31, 2013	879	12,879	1,353,961	10,120,454	-10,668,408	819,765
Balance - shares at Dec. 31, 2013	8,782	12,877,500
Preferred stock and warrants issued for cash	194			1,650,567		1,650,760
Preferred stock and warrants issued for cash - shares	1,941
Modification of warrants				13,132		13,132
Warrants issued for services				281,283		281,283
Common stock issued for payment of preferred stock dividends		1,206	-1,025,404	1,024,198
Common stock issued for payment of preferred stock dividends - shares		1,206,387
Common stock issued for services		40		33,960		-34,000
Common stock issued for services - shares		40,000
Amortization of options issued for services				217,444		217,444
Preferred dividend accrued			640,673	-640,673
Net loss					-2,748,190	-2,748,190
Balance at Dec. 31, 2014	$1,073	$14,124	$969,230	$12,700,365	($13,416,598)	$268,194
Balance - shares at Dec. 31, 2014	10,723	14,123,887

Statement_of_Stockholders_Equi

Statement of Stockholders' Equity (Parenthetical) (USD $)	12 Months Ended
	Dec. 31, 2014
Statement of Stockholders' Equity (Parenthetical)
Offering costs	$289,240

Statements_of_Cash_Flows

Statements of Cash Flows (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
OPERATING ACTIVITIES
Net loss	($2,748,190)	($1,956,872)
Adjustments to reconcile net loss to net cash used in operating activities:
Common stock issued for services	34,000	34,000
Stock options compensation	217,444	667,449
Modification of warrants	13,132
Warrants issued for services	281,283
Depreciation expense		144
Change in derivative liability, net of bifurcation		3,926
Changes in operating assets and liabilities
Change in accounts payable and accrued expenses	26,367	-368,846
Net Cash Used in Operating Activities	-2,175,964	-1,620,199
FINANCING ACTIVITIES
Preferred stock issued for cash, net of stock offering costs	1,650,760	2,829,674
Proceeds from related party notes payable		30,000
Repayment of related party notes payable		-30,000
Net Cash Provided by Financing Activities	1,650,760	2,829,674
NET INCREASE (DECREASE) IN CASH	-525,204	1,209,475
CASH AT BEGINNING OF PERIOD	1,241,397	31,922
CASH AT END OF PERIOD	716,193	1,241,397
CASH PAID FOR:
Interest
Income taxes
NON CASH FINANCING ACTIVITIES:
Executive salary forfeited		104,000
Common stock issued for dividends	1,025,404
Settlement of derivative liability		5,691,185
Preferred dividend accrual	$640,673	$492,089

Note_1_Nature_of_Operations

Note 1 - Nature of Operations	12 Months Ended
	Dec. 31, 2014
Notes
Note 1 - Nature of Operations	NOTE 1 – NATURE OF OPERATIONS
	SignPath Pharma, Inc., (the “Company”) was incorporated under the laws of the State of Delaware on May 15, 2006. The Company was organized to develop proprietary formulations of curcumin (diferuloylmethane), a naturally occurring compound found in the root of the Curcuma longa (turmeric) plant, for applications in malignant diseases. The Company’s product candidates are currently in Phase I clinical trials in Austria and an Investigational New Drug (“IND”) application was approved by the U.S. Food and Drug Administration (“FDA”) in 2014.

Note_2_Going_Concern

Note 2 - Going Concern	12 Months Ended
	Dec. 31, 2014
Notes
Note 2 - Going Concern	NOTE 2 - GOING CONCERN
	The Company's financial statements are prepared using generally accepted accounting principles in the United States of America applicable to a going concern which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company has not yet established an ongoing source of revenues sufficient to cover its operating costs and allow it to continue as a going concern. During the year ended December 31, 2014, the Company recognized sales revenue of~ $-0- and incurred a net loss of $2,748,190. As of December 31, 2014, the Company had an accumulated deficit of $13,416,598. The continuation of the Company as a going concern is dependent upon the continued financial support from its shareholders, the ability to raise equity or debt financing, and the attainment of profitable operations from the Company's planned business. If the Company is unable to obtain adequate capital, it could be forced to cease operations. These consolidated financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.
	In order to continue as a going concern, the Company will need, among other things, additional capital resources. Management's plan is to obtain such resources for the Company by obtaining capital from significant shareholders sufficient to meet its operating expenses and seeking equity and/or debt financing from third parties. However management cannot provide any assurances that the Company will be successful in accomplishing any of its plans.
	The ability of the Company to continue as a going concern is dependent upon its ability to successfully accomplish the plans described in the preceding paragraph and eventually secure other sources of financing and attain profitable operations. The accompanying financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

Note_3_Summary_of_Significant_

Note 3 - Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2014
Notes
Note 3 - Summary of Significant Accounting Policies	NOTE 3 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	Use of Estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.
	Accounting Basis
	The Company’s financial statements are prepared using the accrual basis of accounting in accordance with accounting principles generally accepted in the United States. The Company has elected a December 31 fiscal year end.
	Cash and Cash Equivalents
	The Company considers all highly liquid instruments with maturity of three months or less at the time of issuance to be cash equivalents. There were no cash equivalents as of December 31, 2014 or 2013.
	Concentration of Credit Risk
	Financial instruments, which potentially subject us to concentrations of credit risk, consist principally of cash. Our cash balances are maintained in accounts held by major banks and financial institutions located in the United States.
	The Company occasionally maintains amounts on deposit with a financial institution that are in excess of the federally insured limit of $250,000. The risk is managed by maintaining all deposits in high quality financial institutions. The Company had $437,081 and $991,397 of cash balances in excess of federally insured limits at December 31, 2014 and 2013, respectively.
	Fair Value of Financial Instruments
	In accordance with ASC 820, the carrying value of cash and cash equivalents, accounts receivable and accounts payable approximates fair value due to the short-term maturity of these instruments. ASC 820 clarifies the definition of fair value, prescribes methods for measuring fair value, and establishes a fair value hierarchy to classify the inputs used in measuring fair value as follows:
	Level 1-Inputs are unadjusted quoted prices in active markets for identical assets or liabilities available at the measurement date.
	Level 2-Inputs are unadjusted quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, inputs other than quoted prices that are observable, and inputs derived from or corroborated by observable market data.
	Level 3-Inputs are unobservable inputs which reflect the reporting entity’s own assumptions on what assumptions the market participants would use in pricing the asset or liability based on the best available information.
	The carrying amounts reported in the balance sheets for cash, accounts payable and accrued expenses approximate their fair market value based on the short-term maturity of these instruments.
	Derivative Financial Instruments
	The Company generally does not use derivative financial instruments to hedge exposures to cash-flow risks or market-risks that may affect the fair values of its financial instruments. The Company utilizes various types of financing to fund our business needs, including preferred stock with warrants attached and other instruments not indexed to our stock. The Company is required to record its derivative instruments at their fair value. Changes in the fair value of derivatives are recognized in earnings in accordance with ASC 815.
	Research and Development Costs
	The Company expenses the costs of the development of its pharmaceutical products during the period incurred. The Company incurred research and development expenses of $1,927,851 and $841,502 during the years ended December 31, 2014 and 2013, respectively.
	Stock-Based Compensation
	The Company follows the provisions of ASC 718 which requires all share-based payments to employees, including grants of employee stock options, to be recognized in the income statement based on their fair values. The Company uses the Black-Scholes pricing model for determining the fair value of stock based compensation.
	Equity instruments issued to non-employees for goods or services are accounted for at fair value and are marked to market until service is complete or a performance commitment date is reached, whichever is earlier.
	Income Taxes
	The Company accounts for income taxes under the asset and liability method. Deferred tax assets and liabilities are determined based on differences between the financial reporting and tax bases of assets and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse.
	In July, 2006, the FASB issued ASC 740, Accounting for Uncertainty in Income Taxes, which clarifies the accounting for uncertainty in tax positions taken or expected to be taken in a return. ASC 740 provides guidance on the measurement, recognition, classification and disclosure of tax positions, along with accounting for the related interest and penalties. ASC 740 became effective as of January 1, 2007 and had no impact on the Company’s financial statements.
	The charge for taxation is based on the results for the year as adjusted for items, which are non-assessable or disallowed. It is calculated using tax rates that have been enacted or substantively enacted by the balance sheet date.
	Basic and Diluted Net income (Loss) per Share
	The Company computes net income (loss) per share in accordance with ASC 260 which requires presentation of both basic and diluted earnings per share (EPS) on the face of the income statement. Basic EPS is computed by dividing net income (loss) available to common shareholders (numerator) by the weighted average number of shares outstanding (denominator) during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period using the treasury stock method and convertible preferred stock using the if-converted method. In computing Diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants. Diluted EPS excludes all dilutive potential shares if their effect is anti-dilutive.
	For the years ended December 31, 2014 and 2013, all of the Company’s potentially dilutive securities (warrants, options, convertible preferred stock) were excluded from the computation of diluted earnings per share as they were anti-dilutive.  The total number of potentially dilutive Common Shares that were excluded were 23,922,480 and 22,424,146 at December 31, 2014 and 2013, respectively.
	Recent Accounting Pronouncements
	In June 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2014-10, Development Stage Entities (Topic 915) - Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation (“ASU 2014-10”). ASU 2014-10 eliminates the concept of a development stage entity in its entirety from current accounting guidance. The new guidance eliminates the requirements for development stage entities to (i) present inception-to-date information in the statement of operations, stockholders’ equity and cash flows, (ii) label the financial statements as those of a development state entity, (iii) disclose a description of the development stage activities in which the entity is engaged, and (iv) disclose in the first year in which the entity is no longer a development stage entity that in prior years it and been in the development stage. ASU 2014-10 is effective prospectively for public entities for annual reporting periods beginning after December 15, 2015, and interim periods within those annual periods; however, early adoption is permitted. The Company elected to adopt ASU 2014-10 as permitted, for the financial statements ended September 30, 2014 and, accordingly, has not included the inception-to-date disclosures and other previously required disclosures for development stage entities.

Note_4_Accrued_Liabilities

Note 4 - Accrued Liabilities	12 Months Ended
	Dec. 31, 2014
Notes
Note 4 - Accrued Liabilities	NOTE 4 – ACCRUED LIABILITIES
	Pursuant to the applicable Codification literature, the Company has concluded it is probable that it will pay $85,738 in liquidated damages pursuant to the registration rights clause in certain of the securities sold in fiscal years 2008 and 2009, the Company was required to file a registration statement by January 27, 2009. The Company failed to do so until April 7, 2009, resulting in liquidated damages of 2% per month of the gross proceeds, which approximated $1.8 million as of that date. During the year ended December 31, 2009, the Company’s registration statement covering the securities was declared effective by the SEC. Each holder is entitled to $47.32 per share owned. The Company has resolved to pay the liquidated damages in shares of Common Stock valued at $1.00 per share, pursuant to the terms and provisions of the Certificate of Designation, Preferences and Rights of Series A Convertible Preferred Stock.

Note_5_Note_Payable

Note 5 - Note Payable	12 Months Ended
	Dec. 31, 2014
Notes
Note 5 - Note Payable	NOTE 5 – NOTE PAYABLE
	In January 2013, the Company received $25,000 in cash pursuant to a short-term promissory note with a related party. In March 2013 the Company received $5,000 in cash pursuant to a short-term promissory note with the same related party. The notes did not bear interest. The Company assessed the imputed interest and found the balance to be immaterial. In April 2013, the balance on the notes was repaid in full.

Note_6_Derivative_Liability_an

Note 6 - Derivative Liability and Fair Value Measurements	12 Months Ended
	Dec. 31, 2014
Notes
Note 6 - Derivative Liability and Fair Value Measurements	NOTE 6 – DERIVATIVE LIABILITY AND FAIR VALUE MEASUREMENTS
	On July 17, 2013, the Company amended its Certificate of Incorporation to eliminate anti-dilution price protection from its Series A Preferred Stock and associated derivative liability. The change in fair value during years ended December 31, 2014 and 2013 of $0 and $(3,926), respectively, is recorded as a derivative loss in the accompanying Statements of Operations.

Note_7_Preferred_Stock

Note 7 - Preferred Stock	12 Months Ended
	Dec. 31, 2014
Notes
Note 7 - Preferred Stock	NOTE 7 – PREFERRED STOCK
	The Company has authorized 5,000,000 shares of Preferred Stock, $.10 par value, of which, as of December 31, 2014, an aggregate of 10,722.375 shares were issued and outstanding consisting of (i) 5,000 shares of Series A Convertible Preferred Stock authorized and 3,255.3753,256 shares issued and outstanding, (ii) 3,000 shares of Series B Convertible Preferred Stock authorized and 2,146 shares were issued and outstanding, (iii) 6,000 shares of Series C Convertible Preferred Stock authorized and 5,001 shares were issued and outstanding, and (iv) 6,000 shares of Series D Convertible Preferred Stock are authorized, 320 of which were issued and outstanding.
	Series A Convertible Preferred Stock
	The Series A Convertible Preferred Stock (“Series A Preferred Stock”) was authorized by resolutions adopted by the Company’s Board of Directors and set forth in a Certificate of Designation, Preferences and Rights (“Certificate of Designation”), filed with the Secretary of State of Delaware on November 26, 2008, as amended and restated on July 17, 2013, which contains the designations, rights, powers, preferences, qualifications and limitations of the Series A Preferred Stock.  The shares of Series A Preferred Stock are fully paid and non-assessable.
	Between November 25, 2008 and July 26, 2011, the Company completed the private placement of an aggregate of 3,255.375 Units of the Company’s securities, representing $3,255,375 principal amount of 6.5% Series A Preferred Stock at $1,000 per Unit.  This was the first series of preferred Stock issued by the Company.  Each Unit consisted of:  $1,000 face value of one share of Preferred Stock, convertible at $.85 per share into 1,177 shares of common stock, with each share of Preferred Stock accruing an annual dividend of 6.5% or $65 per share payable annually in cash or shares of common stock at the option of the Company, unless earlier converted or redeemed.  Warrants included in the Units, as amended, are exercisable for five years from the date when the Common Stock is publicly traded at an exercise price of $1.27, payable in cash, unless the Company fails to keep the registration statement effective to purchase 1,177 shares of common stock.  A total of 3,255.375 shares of Preferred Stock were purchased in the offering, which are convertible into an aggregate of approximately 3,831,576 shares of common stock.  Of this amount, an aggregate of 3,382,357 shares have been registered for resale by 33 retail investors, which amount excludes 449,220 shares of common Stock issuable upon conversion of Preferred Stock sold to the Placement Agent’s affiliates.
	Rank.  The Preferred Stock ranks (i) senior to the common stock and any other class or series of the Company’s capital stock either specifically ranking by its terms junior to the Preferred Stock or not specifically ranking by its terms senior to or on parity with the Preferred Stock, (ii) on parity with any class or series of the Company’s capital stock specifically ranking by its terms on parity with the Preferred Stock, and (iii) junior to any class or series of capital stock specifically ranking by its terms senior to the Preferred Stock, in each case, as to payment of dividends or as to distributions of assets upon liquidation, dissolution or winding-up of the Company, whether voluntary or involuntary.  The approval of the holders of a majority of the Preferred Stock is required in order for the Company to issue any capital stock with rights on parity with or senior to the Preferred Stock.
	Dividends.  The holders of the Preferred Stock are entitled to receive annual cumulative per share dividends of 6.5% of the liquidation preference of the Preferred Stock, out of funds legally available, prior to any payment of dividends on the Company’s common stock or any other class of stock ranking junior to the Preferred Stock.  Such dividends are payable in cash or shares of common stock, at the option of the Company, semiannually on the last business day of February and August of each year (each a “Dividend Payment Date”), commencing in February 2009 with respect to the period from issuance through such date.  The holders of the Preferred Stock are entitled to share ratably with the holders of the common stock in any dividend declared on the common stock.
	Dividends on the Preferred Stock will accrue whether or not the Company has earnings, whether or not there are funds legally available for the payment of such dividends and whether or not such dividends are declared.  Dividends accumulate to the extent they are not paid on the Dividend Payment Date to which they relate.  Accumulated unpaid dividends will not bear interest.  According to Delaware law, the Company may declare and pay dividends or make other distributions on its capital stock only out of legally-available funds.  In addition, no dividends or distributions may be declared, paid or made if the Company is or would be rendered insolvent by virtue of such dividend or distribution.
	The Company may not (i) pay any dividends in respect of any shares of capital stock ranking junior to the Preferred Stock (including the common stock), other than dividends payable in the form of additional shares of the same junior stock as that on which such dividend is declared, or (ii) redeem any shares of capital stock ranking junior to the Preferred Stock (including the common stock), unless and until all accumulated and unpaid dividends on the Preferred Stock have been, or contemporaneously are, declared and paid in full.
	Conversion.  At the election of the holder thereof, each share of Preferred Stock will be convertible into common stock, at any time after issuance, at the Conversion Rate, as it may be adjusted from time to time in accordance with the Certificate of Designation.  The Preferred Stock will not convert automatically into Common Stock upon completion of this offering and only the underlying Common Stock issuable upon conversion is registered for the resale under this prospectus.  The Conversion Rate initially will be 1,177 shares of common stock ($.85 per share) for each Share of Preferred Stock.  Conversion Price is also subject to adjustment from time to time in the event of (i) the issuance of common stock as a dividend or distribution on any class of the Company’s capital stock; or (ii) the combination, subdivision or reclassification of the common stock.  No fractional shares will be issued upon conversion.  Payment of accumulated and unpaid dividends will be made upon conversion to the extent of legally-available funds.
	The shares of Preferred Stock may also be converted into common stock at the Conversion Rate at the Company’s option following the effectiveness of a Registration Statement, if the Company’s common stock trades above 200% of the Conversion Rate per share for a period of 20 consecutive trading days.
	Voting Rights.  The affirmative vote of the holders of at least two-thirds of the outstanding shares of Preferred Stock, voting as a class, shall be required to authorize, effect or validate (i) any change in the rights, privileges or preferences of the Preferred Stock that would adversely affect the Preferred Stock, or (ii) the authorization, creation, issuance or increase in the authorized or issued amount of any class or series of stock ranking on parity with or superior to the Preferred Stock with respect to the declaration and payment of dividends or distribution of assets upon liquidation, dissolution or winding-up of our Company.  In addition, the holders of Preferred Stock shall have the right to vote, together with holders of common stock as single class, on all matters upon which the holders of common stock are entitled to vote pursuant to applicable Delaware law or the Company’s Certificate of Incorporation.  The Preferred Stock shall vote on an “as converted basis” with each holder of Preferred Stock having one vote for each Conversion Share underlying such holder’s shares of Preferred Stock.
	Liquidation.  In the event of any voluntary or involuntary liquidation, dissolution or winding-up of the Company, before any payment or distribution of the assets of the Company (whether capital or surplus), or the proceeds thereof, may be made or set apart for the holders common stock or any stock ranking junior to Preferred Stock, the holders of Preferred Stock will be entitled to receive, out of the assets of the Company available for distribution to stockholders, a liquidating distribution of $1,000 per share, plus any accrued and unpaid dividends, subject to adjustment upon the occurrence of certain events.  If, upon any voluntary or involuntary liquidation, dissolution or winding up of the Company, the assets of the Company are insufficient to make the full payment of $1,000 per share, plus all accrued and unpaid dividends on the Preferred Stock and similar payments on any other class of stock ranking on a parity with the Preferred Stock upon liquidation, then the holders of Preferred Stock and such other shares will share ratably in any such distribution of the Company’s assets in proportion to the full respective distributable amounts to which they are entitled.  Certain events, including a consolidation or merger of the Company with or into another corporation or sale or conveyance of all or substantially all the property and assets of the Company will be deemed to be a liquidation, dissolution or winding-up of the Company for purposes of the foregoing.
	Miscellaneous.  The Company is not subject to any mandatory redemption or sinking fund provision with respect to the Preferred Stock.  The holders of the Preferred Stock are not entitled to preemptive rights to subscribe for or to purchase any shares or securities of any class which may at any time be issued, sold or offered for sale by the Company.  Shares of Preferred Stock redeemed or otherwise reacquired by the Company shall be retired and shall be unavailable for subsequent issuance as any class of the Company’s preferred stock.
	Series B Convertible Preferred Stock
	The Series B Convertible Preferred Stock (“Series B Preferred Stock”) has been authorized by resolutions adopted by the Company’s Board of Directors and set forth in a Certificate of Designation filed with the Secretary of State of Delaware on September 2, 2011, which contains the designations, rights, powers, preferences, qualifications and limitations of the Series B Preferred Stock.  The shares of Series B Preferred Stock are fully paid and non-assessable.
	The Conversion Rate and dividend rates are the same for Series A and Series B Preferred Stock; however, the Series A Preferred Stock is senior to the Series B Preferred Stock on sale or liquidation of the Company.  Each share of Series B Preferred Stock is convertible at $.85 per share into an aggregate of 1,177 shares of common stock, with each share of Series B Preferred Stock accruing an annual dividend of 6.5% or $65 per share payable annually in cash or shares of common stock at the option of the Company, unless earlier converted or redeemed on the same terms as the Series A Preferred Stock.  The Series B Preferred Stock votes on an as converted basis with the Common Stock and Series A Preferred Stock having one vote for each share issuable upon conversion of the Series B Preferred Stock.
	Series C Convertible Preferred Stock
	The Series C Convertible Preferred Stock (“Series C Preferred Stock”) has been authorized by resolutions adopted by the Company’s Board of Directors and set forth in a Certificate of Designation, Preferences and Rights (“Certificate of Designation”), filed with the Secretary of State of Delaware on March 12, 2013, which contains the designations, rights, powers, preferences, qualifications and limitations of the Series C Preferred Stock.  The shares of Series C Preferred Stock are fully paid and non-assessable.
	The dividend rate of 6.5% per annum and the terms of the dividends are the same as Series A and B Preferred Stock.  The Conversion Rate is 800 shares of Common Stock (at $1.25 per share) for each $1,000 stated value of Series C Preferred Stock and may be converted into Common Stock by the Company following the effectiveness of a registration statement if the Company’s Common Stock trades above 300% of the Conversion Rate for 10 consecutive trading days. The Series C Preferred Stock ranks on parity with the Series B Preferred Stock and junior to the Series A Preferred Stock on sale or liquidation of the Company.  The Series C Preferred Stock votes on an as converted basis with the Common Stock and Series A and B Preferred Stock having one vote for each share issuable upon conversion of the Series C Preferred Stock
	Series D Convertible Preferred Stock
	The Series D Convertible Preferred Stock (“Series D Preferred Stock”) has been authorized by resolutions adopted by the Company’s Board of Directors and set forth in a Certificate of Designation, Preferences and Rights, filed with the Secretary of State of Delaware on September 22, 2014, which contains the designations, rights, powers, preferences, qualifications and limitations of the Series C Preferred Stock.  The shares of Series D Preferred Stock are fully paid and non-assessable.
	The dividend rate of 6.5% per annum and the terms of the dividends are the same as Series A, B and C Preferred Stock.  The Conversion Rate is 500 shares of Common Stock (at $2.00 per share) for each $1,000 stated value of Series D Preferred Stock and maybe converted into Common Stock following the effectiveness of a registration statement if the Company’s Common Stock trades above 200% of the Conversion Rate for 10 consecutive trading days.  The Series D Preferred Stock ranks on parity with the Series B and C Preferred Stock and junior to the Series A Preferred Stock on sale or liquidation of the Company.  The Series D Preferred Stock votes on an as converted basis with the Common Stock and Series A, B and C Preferred Stock having one vote for each share issuable upon conversion of the Preferred Stock.

Note_8_Common_Stock

Note 8 - Common Stock	12 Months Ended
	Dec. 31, 2014
Notes
Note 8 - Common Stock	NOTE 8 – COMMON STOCK
	During year ended December 31, 2014, the Company issued 40,000 shares of common stock to the Chairman of the Audit Committee for services which were valued at $34,000 based on $0.85 per share fair value of common stock.  The Company also settled $1,024,198 of accrued dividends payable by issuing 1,206,387 shares of common stock to Series A Preferred shareholders valued at $.85 per share.
	During year ended December 31, 2013, the Company issued 40,000 shares of common stock, for services performed at $0.85 per share. The 40,000 issued in the quarter ended March 31, 2013 were not issued until the current year and were booked initially as a stock payable in the amount of $34,000 valued at the stock price on February 20, 2013 of $0.85. As of December 31, 2013, stock payable was $-0-.

Note_9_Warrants

Note 9 - Warrants	12 Months Ended
	Dec. 31, 2014
Notes
Note 9 - Warrants	NOTE 9 – WARRANTS
	A summary of the status of the Company's warrants as of December 31, 2014 and 2013 are presented below:
		Number of Warrants	Weighted Average Exercise Price		Weighted Average Grant Date Fair Value		Expiration Date (yrs)	Value if Exercised
	Outstanding as of December 31, 2012	8,674,372	$	1.03	$	0.85	2.90	$	8,957,486
	Granted	4,344,392		1.15		0.85	3.70		5,008,864
	Cancelled/Expired	-		-		-	-		-
	Outstanding as of December 31, 2013	13,018,764		1.07		0.85	4.88		13,966,350
	Granted	2,071,011		1.40		0.85	4.88		2,893,701
	Cancelled/Expired	(2,539,713)		(1.27)		-	-		(1,160,957)
	Outstanding as of December 31, 2014	12,550,062	$	1.25	$	0.85	4.60	$	15,699,094
	As of December 1, 2013, the Company’s Board of Directors extended the terms of all outstanding warrants, some of which were set to expire in 2014 or 2015, such that none of the warrants expire before the fifth anniversary of the date on which the Company’s common stock begins trading on a national securities exchange, the OTC Bulletin Board or OTC Pink. The Company valued these warrants using the Black-Scholes option pricing model under the following assumptions: $0.85 and $1.27 stock price, $0.85 and $1.27 exercise price, expected term of 5 years, 107.73% volatility, .10% to 143% risk free rate. The Company recorded a deemed dividend of $2,445,621 related to the extensions.
	During the year ended December 31, 2013, the Company extended the exercise period of 3,226,032 Class A warrants with an exercise price of $0.85 to expire on the fifth anniversary of the next registration statement to be filed. The Company valued these warrants using the Black-Scholes option pricing model under the following assumptions: $0.85 stock price, $0.85 exercise price, 5 to 7 years to maturity, 107% to 112% volatility, .96% to 2.26% risk free rate.  As a result of the modification the value of the replacement placement warrants was less than the valuation of the original warrants, therefore the Company did not recognize a gain on equity modification.
	On February 20, 2013, the Company issued 400,000 warrants to its vendor for curcumin. The warrants have an exercise price of $0.85 per share and have a life of five years from the effective date of a registration statement.  The Company valued these warrants using the Black-Scholes option pricing model under the following assumptions: $0.85 stock price, $0.85 exercise price, 5 years to maturity, 885% volatility, .85% risk free rate. The Company recorded expense of $339,997 related to these warrants for the year ended December 31, 2013.
	During the year ended December 31, 2013, the Company issued 1,087,552 warrants as stock offering costs to the Company’s placement agent. The warrants were not deemed to be derivative instruments because they do not have a reset feature, and therefore no liability was booked related to the warrants.
	The Company will issue cash or warrants as stock offering costs. The Company recognizes the cost upon completion of the share purchase. Warrants are valued and recorded using the Black-Scholes option pricing model. Total stock issuance costs for December 31, 2014 and 2013 were $289,240 and $550,326, respectively.
	The Company also issued 200,000 warrants to its vendor for curcumin on January 24, 2014. The warrants have an exercise price of $1.875 per share and have a life of five years from the effective date of a registration statement. The Company valued these warrants using the Black-Scholes option pricing model under the following assumptions: $0.85 stock price, $2.00 exercise price, 5 years to maturity, 123.35% volatility, 1.75% risk free rate. As a result of the Company recognized a research and development expense of $130,249.
	The Company also issued 200,000 warrants to its vendor for curcumin on December 12, 2014. The warrants have an exercise price of $2.00 per share and have a life of seven years from the effective date of a registration statement. The Company valued these warrants using the Black-Scholes option pricing model under the following assumptions: $0.85 stock price, $2.00 exercise price, 7 years to maturity, 132.88% volatility, 1.75% risk free rate. As a result of the Company recognized a research and development expense of $151,034.
	During the year ended December 31, 2014, the Company issued 443,800 warrants as stock offering costs to the Company’s placement agent. The warrants were not deemed to be derivative instruments because they do not have a reset feature, and therefore no liability was booked related to the warrants.
	On May 28, 2014, the Company voided 1,537,840 placement warrants which were replaced by 1,484,851 placement agent warrants with an exercise price of $1.25 which will expire on the seventh anniversary of the modification. The Company modified the terms of the warrants from $0.85 exercise price to $1.25.The Company valued these warrants using the Black-Scholes option pricing model under the following assumptions: $0.85 stock price, $1.25 exercise price, 7 5 years to maturity, 117.07% volatility, 2.01% risk free rate. As a result of the modification the value of the replacement placement warrants was less than the valuation of the original warrants, therefore the Company did not recognize a gain on equity modification.
	On July 22, 2014, the Company voided and replaced 2,092,051 placement agent warrants with an exercise price of $0.85 to $1.25 which will expire on the seventh anniversary of the modification. The Company modified the terms so all warrants had an exercise price of $1.25. The Company valued these warrants using the Black-Scholes option pricing model under the following assumptions: $0.85 stock price, $0.85 exercise price, 5 to 7 years to maturity, 99.66% volatility, 1.91% to 2.13% risk free rate. As a result of the modification, the Company recognized a loss on equity modification of $13,132.

Note_10_Stock_Options

Note 10 - Stock Options	12 Months Ended
	Dec. 31, 2014
Notes
Note 10 - Stock Options	NOTE 10 – STOCK OPTIONS
	The Company’s 2009 Employee Stock Incentive Plan (the “2009 Plan”) was adapted by the Company’s Board of Directors on February 9, 2009 in order to motivate participants by means of stock options and restricted stock to achieve the Company’s long-term performance goals and enable our employees, officers, directors and consultants to participate in our long term growth and financial success. The 2009 Plan, which is administered by our Board of Directors, currently authorizes the issuance of a maximum of 1,171,630 (as of January 1, 2015) shares of our common stock, which may be authorized and unissued shares or treasury shares. On February 13, 2013, the Board of Directors authorized an amendment to the 2009 Plan to increase the number of authorized options and shares to 1,000,000 plus on a yearly basis by 10% of the amount of shares issued during the prior year. Employee options shall be deemed Incentive Stock Options (as defined in the 2009 Option Plan) to the maximum extent permitted by Section 422 of the Internal Revenue Code including a five-year limit on exercise for 10% or greater stockholders with any excess grant to the above individuals over the limits set by Section 422 being Non-Qualified Stock Options as defined in the 2009 Option Plan. Both the Incentive Stock Options or any Non-Qualified Stock Options must be granted at an exercise price of not less than the fair market value of shares of common stock at the time the option is granted and Incentive Stock Options granted to 10% or greater stockholders must be granted at an exercise price of not less than 110% of the fair market value of the shares on the date of grant.
	If any award under the 2009 Plan terminates, expires unexercised, or is cancelled, the shares of common stock that would otherwise have been issuable pursuant thereto will be available for issuance pursuant to the grant of new awards. The 2009 Plan will terminate on February 9, 2019. As of December 31, 2014, an aggregate of 855,000 options had been granted under the plan, as follows:
		Number of Options	Weighted Average Exercise Price		Weighted Average Grant Date Fair Value		Expiration Date (yrs)	Value if Exercised
	Outstanding as of December 31, 2012	100,000	$	0.85	$	0.85	7.50	$	85,000
	Granted	470,000		0.95		0.85	5.00		447,500
	Cancelled/Expired	-		-		-	-		-
	Outstanding as of December 31, 2013	570,000		0.93		0.85	4.56		532,500
	Granted	285,000		1.32		0.85	5.06		375,000
	Cancelled/Expired	-		-		-	-		-
	Outstanding as of December 31, 2014	855,000	$	1.06	$	0.85	3.84	$	907,500
	1During the year ended December 31, 2013, the Company issued an aggregate of 240,000 options to two members of its board of directors, 82,400 non-qualified stock options to its CEO and a member of its board of directors, and 117,600 incentive options to its CEO and a member of its board of directors under the 2009 plan for compensation during 2013. The options have exercise prices of $.85 and $1.25 per share and have a life of five years. The options vest as follows: one fourth on the date of grant, one fourth on every quarter from grant date. The Company valued these options using the Black-Scholes option pricing model totaling $51,000 under the following assumptions: $0.85 stock price, $.85 and $1.25 exercise prices, 5 years to maturity, 649% volatility, .35% risk free rate. As of December 31, 2013, these options were fully vested and expensed.
	2In 2013, the Company also issued 30,000 options to its law firm under the 2009 Plan. The options have an exercise price of $0.85 per share and have a life of five years. The options vest as follows: one fourth on the date of grant, one fourth on every quarter from grant date. The Company valued these options using the Black-Scholes option pricing model totaling $25,500 under the following assumptions: $0.85 stock price, $0.85 exercise price, 5 years to maturity, 885% volatility 88% risk free rate.
	3During the year ended December 31, 2014, the Company issued an aggregate 60,000 options to two members of its board of directors and under the 2009 plan for compensation during 2014. The options have an exercise price of $1.25 per share and have a life of five years. The options vest as follows: one fourth on the date of grant, one fourth on every quarter from grant date. The Company valued these options using the Black-Scholes option pricing model totaling $43,226 under the following assumptions: $0.85 stock price, $1.25 exercise price, 2.69 years to maturity, 305% volatility, .64% risk free rate.
	4The Company issued 225,000 options to its CEO and a member of its board of directors under the 2009 plan. The options have an exercise price of $1.25 to $2.00 per share and have a life of five years. The options vest immediately on grant date. The Company valued these options using the Black-Scholes option pricing model totaling $179,232 under the following assumptions: $0.85 stock price, $1.25 to $2.00 exercise price, 5 years to maturity, 286.96% to 415.87% volatility, 1.66% to 1.92% risk free rate.
	The Company has recorded amortization expense of $217,444 and $667,449 related to these options for the years ended December 31, 2014 and 2013.

Note_11_Income_Taxes

Note 11 - Income Taxes	12 Months Ended
	Dec. 31, 2014
Notes
Note 11 - Income Taxes	NOTE 11 – INCOME TAXES
	The Company’s provision for income taxes was $0 for the years ended December 31, 2014 and 2013 respectively since the Company incurred net operating losses which have a full valuation allowance through December 31, 2014.
	ASC 740 requires the reduction of deferred tax assets by a valuation allowance if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. In the Company’s opinion, it is uncertain whether they will generate sufficient taxable income in the future to fully utilize the net deferred tax asset. Accordingly, a full valuation allowance equal to the deferred tax asset has been recorded. The total deferred tax asset is calculated by multiplying a 39% marginal tax rate by the cumulative Net Operating Loss (“NOL”) of $10,171,765. The total valuation allowance is equal to the total deferred tax asset. The valuation allowance increased by $1,066,672 from $2,900,316 to $3,966,988 for the year ended December 31, 2014.
	The tax effects of significant items comprising the Company's net deferred taxes as of December 31, 2014 and 2013 were as follows:
		2014		2013
	Cumulative NOL	$	10,171,765	$	7,436,707
	Deferred Tax assets:
	Net operating loss carry forwards		3,966,988		2,900,316
	Valuation allowance		(3,966,988)		(2,900,316)
		$	-	$	-
	The income tax provision differs from the amount of income tax determined by applying the U.S. federal and state income tax rates of 39% to pretax income from continuing operations for the years ended December 31, 2014 and 2013 due to the following:
		2014		2013
	Income tax benefit at U. S. federal statutory rates:	$	(1,071,794)	$	(763,180)
	Stock-based compensation		-		273,565
	Derivative liability		-		1,531
	Modification of warrants		5,121		-
	Change in valuation allowance		1,066,673		488,084
		$	-	$	-
	The Company adopted the provisions of ASC 740 at the beginning of fiscal year 2008. As a result of this adoption, the Company has not made any adjustments to deferred tax assets or liabilities. The Company did not identify any material uncertain tax positions on returns that have been filed or that will be filed. The Company did not recognize any interest or penalties for unrecognized tax benefits during the years ended December 31, 2014 and 2013, nor were any interest or penalties accrued as of December 31, 2014.
	The Company has filed income tax returns in the United States and Pennsylvania. All tax years prior to 2010 are closed by expiration of the statute of limitations. The years ended December 31, 2014, 2013, 2012, and 2011 are open for examination.
	The Company’s net state and federal operating loss carry forwards of approximately $9,605,038 expire in various years beginning in 2028 and carrying forward through 2034.
	The Company has had numerous transactions in its common stock. Such transactions may have resulted in a change in the Company's ownership, as defined in the Internal Revenue Code Section 382. Such change may result in an annual limitation on the amount of the Company's taxable income that may be offset with its net operating loss carry forwards. The Company has not evaluated the impact of Section 382, if any, on its ability to utilize its net operating loss carry forwards in future years.

Note_12_Related_Party_Transact

Note 12 - Related Party Transactions	12 Months Ended
	Dec. 31, 2014
Notes
Note 12 - Related Party Transactions	NOTE 12 – RELATED PARTY TRANSACTIONS
	On January 31, 2013, the Company signed a demand promissory note with a related party. The principal sum of the note was $25,000, bearing no interest.
	On March 4, 2013, the Company signed a demand promissory note with a related party. The principal sum of the note was $5,000, bearing no interest.
	On March 1, 2013, the Company paid the principal sum of $30,000 on the demand promissory notes described above.

Note_13_Commitment_and_Conting

Note 13 - Commitment and Contingencies	12 Months Ended
	Dec. 31, 2014
Notes
Note 13 - Commitment and Contingencies	NOTE 13 – COMMITMENT AND CONTINGENCIES
	SignPath is obligated to pay running royalties of 2.5% on net sales of less than $250 million for products covered by an issued patent licensed under the UTMDACC License Agreement. This royalty rate increases to 3% for sales equal to, or greater than, $250 million. A royalty of 1.5% of net sales is payable by SignPath for products covered under the license which are not protected by an issued patent. After sales to the public begin, SignPath must pay a minimum annual royalty $75,000 which can be deducted from the royalties on net sales due under the agreement. In addition, SignPath is obligated to pay 20% to 25% of all non-royalty consideration received under sublicensing agreements.
	SignPath was obligated under the JHU License Agreement to pay $50,000 in license fees which have been paid, plus minimum annual royalties increasing from $10,000 in the first two years to $25,000 in the third and fourth years and $30,000 in the fifth year. An aggregate of approximately $160,000 has been paid under this license agreement. The JHU License Agreement also provides that we will be obligated to pay JHU running royalty rates of two percent (2%) of net sales less than $250 million for licensed products covered by one or more claims in an issued patent, and three percent (3%) of net sales equal to or greater than $250 million for licensed products covered by one or more claims in an issued patent, or one and one half percent (1.5%) of net sales of licensed products not covered by an issued patent. The running royalties payable under the agreement are subject to a minimum annual rate. SignPath is also subject to other substantial payments, including all reasonable costs of patent reimbursement. The Company is obligated to make the following payments upon development milestones to JHU regardless of whether the milestone is achieved by the Company, a sublicensee or an affiliate: (1) $25,000 upon dosing the first patient with a licensed product in a Phase I clinical trial at a site other than JHU; (2) $50,000 upon dosing the first patient with a licensed patent in a Phase II clinical trial at a site other than JHU; (3) $25,000 upon dosing the first patient with the licensed patent in a Phase III clinical trial at a site other than JHU; (4) $250,000 upon first regulatory approval of the licensed patent, or $100,000 if no patent has issued; (5) $10,000 upon issuance of a patent sublicense fees (if applicable), and reimbursement of costs reasonably incurred by JHU in connection with the patent.
	SignPath and JHU entered into an Exclusive License Agreement effective June 5, 2013 (the “2013 Agreement”) as a result of an invention developed during the course of research created under the above-described JHU License Agreement.  JHU granted the Company an exclusive worldwide license to use “a composite polymeric nanoparticle for overcoming multidrug resistance to cancer chemotherapeutics and treatment-related systemic toxicity.”  The license fee was $10,000 upon signing; $15,000 within one year; with minimum annual royalties starting in year three at $10,000; $20,000 in year four and $30,000 in year five and onward.  SignPath will also pay an earned royalty of 3% on sales to be reduced by the minimum annual royalty.  Royalties will be paid for a minimum of ten years from first commercial sale of the licensed product.  Milestone payments will be paid by the Company based upon dosing of first patents in Phases I, II, and III clinical trials and then upon regulatory approval, increasing from $25,000 to $150,000.  The 2013 Agreement will continue with the last to expire patent in each country, or if no patents are issued then 20 years from June 5, 2013, subject to earlier termination.
	On December 12, 2014, the Board of Directors authorized an amendment to Dr. Helson’s employment agreement to provide that: (A) upon successful completion of Phase I trials for anti-Ebola testing in Africa paid for by the United States Army Medical Research Institute of Infectious Diseases (“USAMRIID”), exclusive of the cost of drug products and shipping, Dr. Helson would receive options to purchase 300,000 shares of Common Stock exercisable at then current fair market value and a cash bonus of $75,000, and (B) upon successful completion of Phase I trials in Vienna, Austria for the lead anti-QT prolongation drugs (Moxifloxacin) for liposomes Dr. Helson would receive additional options to purchase 300,000 shares of Common Stock exercisable at then current fair market value and a cash bonus of $75,000.

Note_14_Subsequent_Events

Note 14 - Subsequent Events	12 Months Ended
	Dec. 31, 2014
Notes
Note 14 - Subsequent Events	NOTE 14 – SUBSEQUENT EVENTS
	In accordance with ASC 855-10 Company management reviewed all material events through the date of this report and had the following material subsequent events to report. Pursuant to the terms of a Letter Agreement dated July 12, 2010, Jack Levine received 40,000 restricted shares of Common Stock on January 1, 2015, in consideration of 2014 consulting and accounting services as chairman of the Company’s Audit Committee.
	From January 1, 2015 through March 31, 2015, the Company sold an additional 945.25 Units of Series D Preferred Stock at $1,000 per Unit, to 18 different investors for aggregate proceeds of $945,250.  Meyers Associates L.P. received sales commissions of 10% ($94,525) of the gross proceeds of the sale of Units, as well as a non-accountable expense allowance equal to 3% of the gross proceeds of the Offering and received a Unit Purchase warrant (a portion of which was subsequently transferred to Meyers Investments Family Limited Partnership) to purchase 20% of the shares sold in the Offering. The Company issued 118,157 Series D warrants as part of the subsequent Series D Preferred Stock sold. Warrants are valued and recorded using the Black-Scholes option pricing model valued at $88,144.
	The Company issued 118,157 placement warrants as stock offering costs during 2015. The Company recognizes the cost upon completion of the share purchase. Warrants are valued and recorded using the Black-Scholes option pricing model. Total stock issuance costs subsequent to December 31, 2014 totaled $90,187.
	On January 14, 2015, the Company voided and were replaced by 2,621,851.22 placement agent warrants with an exercise price of $1.25 which will expire on the seventh anniversary of the modification. The replacement warrants have the same terms as the original warrants that were consolidated. The Company valued these warrants using the Black-Scholes option pricing model under the following assumptions: $0.85 stock price, $1.25 exercise price, 7 years to maturity, 144.70% volatility, 1.62% risk free rate. As a result of the modification, the Company recognized a loss on equity modification of $24,868.

Note_3_Summary_of_Significant_1

Note 3 - Summary of Significant Accounting Policies: Use of Estimates (Policies)	12 Months Ended
	Dec. 31, 2014
Policies
Use of Estimates	Use of Estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

Note_3_Summary_of_Significant_2

Note 3 - Summary of Significant Accounting Policies: Accounting Basis (Policies)	12 Months Ended
	Dec. 31, 2014
Policies
Accounting Basis	Accounting Basis
	The Company’s financial statements are prepared using the accrual basis of accounting in accordance with accounting principles generally accepted in the United States. The Company has elected a December 31 fiscal year end.

Note_3_Summary_of_Significant_3

Note 3 - Summary of Significant Accounting Policies: Cash and Cash Equivalents (Policies)	12 Months Ended
	Dec. 31, 2014
Policies
Cash and Cash Equivalents	Cash and Cash Equivalents
	The Company considers all highly liquid instruments with maturity of three months or less at the time of issuance to be cash equivalents. There were no cash equivalents as of December 31, 2014 or 2013.

Note_3_Summary_of_Significant_4

Note 3 - Summary of Significant Accounting Policies: Concentration of Credit Risk (Policies)	12 Months Ended
	Dec. 31, 2014
Policies
Concentration of Credit Risk	Concentration of Credit Risk
	Financial instruments, which potentially subject us to concentrations of credit risk, consist principally of cash. Our cash balances are maintained in accounts held by major banks and financial institutions located in the United States.
	The Company occasionally maintains amounts on deposit with a financial institution that are in excess of the federally insured limit of $250,000. The risk is managed by maintaining all deposits in high quality financial institutions. The Company had $437,081 and $991,397 of cash balances in excess of federally insured limits at December 31, 2014 and 2013, respectively.

Note_3_Summary_of_Significant_5

Note 3 - Summary of Significant Accounting Policies: Fair Value of Financial Instruments (Policies)	12 Months Ended
	Dec. 31, 2014
Policies
Fair Value of Financial Instruments	Fair Value of Financial Instruments
	In accordance with ASC 820, the carrying value of cash and cash equivalents, accounts receivable and accounts payable approximates fair value due to the short-term maturity of these instruments. ASC 820 clarifies the definition of fair value, prescribes methods for measuring fair value, and establishes a fair value hierarchy to classify the inputs used in measuring fair value as follows:
	Level 1-Inputs are unadjusted quoted prices in active markets for identical assets or liabilities available at the measurement date.
	Level 2-Inputs are unadjusted quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, inputs other than quoted prices that are observable, and inputs derived from or corroborated by observable market data.
	Level 3-Inputs are unobservable inputs which reflect the reporting entity’s own assumptions on what assumptions the market participants would use in pricing the asset or liability based on the best available information.
	The carrying amounts reported in the balance sheets for cash, accounts payable and accrued expenses approximate their fair market value based on the short-term maturity of these instruments.

Note_3_Summary_of_Significant_6

Note 3 - Summary of Significant Accounting Policies: Derivative Financial Instruments (Policies)	12 Months Ended
	Dec. 31, 2014
Policies
Derivative Financial Instruments	Derivative Financial Instruments
	The Company generally does not use derivative financial instruments to hedge exposures to cash-flow risks or market-risks that may affect the fair values of its financial instruments. The Company utilizes various types of financing to fund our business needs, including preferred stock with warrants attached and other instruments not indexed to our stock. The Company is required to record its derivative instruments at their fair value. Changes in the fair value of derivatives are recognized in earnings in accordance with ASC 815.

Note_3_Summary_of_Significant_7

Note 3 - Summary of Significant Accounting Policies: Research and Development Costs (Policies)	12 Months Ended
	Dec. 31, 2014
Policies
Research and Development Costs	Research and Development Costs
	The Company expenses the costs of the development of its pharmaceutical products during the period incurred. The Company incurred research and development expenses of $1,927,851 and $841,502 during the years ended December 31, 2014 and 2013, respectively.

Note_3_Summary_of_Significant_8

Note 3 - Summary of Significant Accounting Policies: Stock-based Compensation (Policies)	12 Months Ended
	Dec. 31, 2014
Policies
Stock-based Compensation	Stock-Based Compensation
	The Company follows the provisions of ASC 718 which requires all share-based payments to employees, including grants of employee stock options, to be recognized in the income statement based on their fair values. The Company uses the Black-Scholes pricing model for determining the fair value of stock based compensation.
	Equity instruments issued to non-employees for goods or services are accounted for at fair value and are marked to market until service is complete or a performance commitment date is reached, whichever is earlier.

Note_3_Summary_of_Significant_9

Note 3 - Summary of Significant Accounting Policies: Income Taxes (Policies)	12 Months Ended
	Dec. 31, 2014
Policies
Income Taxes	Income Taxes
	The Company accounts for income taxes under the asset and liability method. Deferred tax assets and liabilities are determined based on differences between the financial reporting and tax bases of assets and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse.
	In July, 2006, the FASB issued ASC 740, Accounting for Uncertainty in Income Taxes, which clarifies the accounting for uncertainty in tax positions taken or expected to be taken in a return. ASC 740 provides guidance on the measurement, recognition, classification and disclosure of tax positions, along with accounting for the related interest and penalties. ASC 740 became effective as of January 1, 2007 and had no impact on the Company’s financial statements.
	The charge for taxation is based on the results for the year as adjusted for items, which are non-assessable or disallowed. It is calculated using tax rates that have been enacted or substantively enacted by the balance sheet date.

Recovered_Sheet1

Note 3 - Summary of Significant Accounting Policies: Basic and Diluted Net Income (loss) Per Share (Policies)	12 Months Ended
	Dec. 31, 2014
Policies
Basic and Diluted Net Income (loss) Per Share	Basic and Diluted Net income (Loss) per Share
	The Company computes net income (loss) per share in accordance with ASC 260 which requires presentation of both basic and diluted earnings per share (EPS) on the face of the income statement. Basic EPS is computed by dividing net income (loss) available to common shareholders (numerator) by the weighted average number of shares outstanding (denominator) during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period using the treasury stock method and convertible preferred stock using the if-converted method. In computing Diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants. Diluted EPS excludes all dilutive potential shares if their effect is anti-dilutive.
	For the years ended December 31, 2014 and 2013, all of the Company’s potentially dilutive securities (warrants, options, convertible preferred stock) were excluded from the computation of diluted earnings per share as they were anti-dilutive.  The total number of potentially dilutive Common Shares that were excluded were 23,922,480 and 22,424,146 at December 31, 2014 and 2013, respectively.

Recovered_Sheet2

Note 3 - Summary of Significant Accounting Policies: Recent Accounting Pronouncements (Policies)	12 Months Ended
	Dec. 31, 2014
Policies
Recent Accounting Pronouncements	Recent Accounting Pronouncements
	In June 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2014-10, Development Stage Entities (Topic 915) - Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation (“ASU 2014-10”). ASU 2014-10 eliminates the concept of a development stage entity in its entirety from current accounting guidance. The new guidance eliminates the requirements for development stage entities to (i) present inception-to-date information in the statement of operations, stockholders’ equity and cash flows, (ii) label the financial statements as those of a development state entity, (iii) disclose a description of the development stage activities in which the entity is engaged, and (iv) disclose in the first year in which the entity is no longer a development stage entity that in prior years it and been in the development stage. ASU 2014-10 is effective prospectively for public entities for annual reporting periods beginning after December 15, 2015, and interim periods within those annual periods; however, early adoption is permitted. The Company elected to adopt ASU 2014-10 as permitted, for the financial statements ended September 30, 2014 and, accordingly, has not included the inception-to-date disclosures and other previously required disclosures for development stage entities.

Note_9_Warrants_Schedule_of_St

Note 9 - Warrants: Schedule of Stockholders' Equity Note, Warrants or Rights (Tables)	12 Months Ended
	Dec. 31, 2014
Tables/Schedules
Schedule of Stockholders' Equity Note, Warrants or Rights
		Number of Warrants	Weighted Average Exercise Price		Weighted Average Grant Date Fair Value		Expiration Date (yrs)	Value if Exercised
	Outstanding as of December 31, 2012	8,674,372	$	1.03	$	0.85	2.90	$	8,957,486
	Granted	4,344,392		1.15		0.85	3.70		5,008,864
	Cancelled/Expired	-		-		-	-		-
	Outstanding as of December 31, 2013	13,018,764		1.07		0.85	4.88		13,966,350
	Granted	2,071,011		1.40		0.85	4.88		2,893,701
	Cancelled/Expired	(2,539,713)		(1.27)		-	-		(1,160,957)
	Outstanding as of December 31, 2014	12,550,062	$	1.25	$	0.85	4.60	$	15,699,094

Note_10_Stock_Options_Schedule

Note 10 - Stock Options: Schedule of Share-based Compensation, Stock Options (Tables)	12 Months Ended
	Dec. 31, 2014
Tables/Schedules
Schedule of Share-based Compensation, Stock Options
		Number of Options	Weighted Average Exercise Price		Weighted Average Grant Date Fair Value		Expiration Date (yrs)	Value if Exercised
	Outstanding as of December 31, 2012	100,000	$	0.85	$	0.85	7.50	$	85,000
	Granted	470,000		0.95		0.85	5.00		447,500
	Cancelled/Expired	-		-		-	-		-
	Outstanding as of December 31, 2013	570,000		0.93		0.85	4.56		532,500
	Granted	285,000		1.32		0.85	5.06		375,000
	Cancelled/Expired	-		-		-	-		-
	Outstanding as of December 31, 2014	855,000	$	1.06	$	0.85	3.84	$	907,500

Note_11_Income_Taxes_Schedule_

Note 11 - Income Taxes: Schedule of Deferred Tax Assets and Liabilities (Tables)	12 Months Ended
	Dec. 31, 2014
Tables/Schedules
Schedule of Deferred Tax Assets and Liabilities
		2014		2013
	Cumulative NOL	$	10,171,765	$	7,436,707
	Deferred Tax assets:
	Net operating loss carry forwards		3,966,988		2,900,316
	Valuation allowance		(3,966,988)		(2,900,316)
		$	-	$	-

Note_11_Income_Taxes_Schedule_1

Note 11 - Income Taxes: Schedule of Effective Income Tax Rate Reconciliation (Tables)	12 Months Ended
	Dec. 31, 2014
Tables/Schedules
Schedule of Effective Income Tax Rate Reconciliation
		2014		2013
	Income tax benefit at U. S. federal statutory rates:	$	(1,071,794)	$	(763,180)
	Stock-based compensation		-		273,565
	Derivative liability		-		1,531
	Modification of warrants		5,121		-
	Change in valuation allowance		1,066,673		488,084
		$	-	$	-

Note_1_Nature_of_Operations_De

Note 1 - Nature of Operations (Details)	12 Months Ended
	Dec. 31, 2014
Details
Entity Incorporation, State Country Name	Delaware
Entity Incorporation, Date of Incorporation	15-May-06

Note_2_Going_Concern_Details

Note 2 - Going Concern (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Details
REVENUES
Net loss	2,748,190	1,956,872
Accumulated deficit	$13,416,598	$10,668,408

Recovered_Sheet3

Note 3 - Summary of Significant Accounting Policies: Concentration of Credit Risk (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Details
Cash, FDIC Insured Amount	$250,000
Cash balance in excess of federally insured limit	$437,081	$991,397

Recovered_Sheet4

Note 3 - Summary of Significant Accounting Policies: Research and Development Costs (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Details
Research and development	$1,927,851	$841,502

Recovered_Sheet5

Note 3 - Summary of Significant Accounting Policies: Basic and Diluted Net Income (loss) Per Share (Details)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Details
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	23,922,480	22,424,146

Note_4_Accrued_Liabilities_Det

Note 4 - Accrued Liabilities (Details) (USD $)	Dec. 31, 2014	Apr. 07, 2009
Details
Probable liquidated damages	$85,738
Liquidated damages		$1,800,000	[1]
[1]	December 31, 2009, the Company's registration statement covering the securities was declared effective by the SEC. Each holder is entitled to $47.32 per share owned. The Company has resolved to pay the liquidated damages in shares of Common Stock valued at $1.00 per share, pursuant to the terms and provisions of the Certificate of Designation, Preferences and Rights of Series A Convertible Preferred Stock.

Note_5_Note_Payable_Details

Note 5 - Note Payable (Details) (USD $)	1 Months Ended				12 Months Ended
	Mar. 31, 2013		Jan. 31, 2013		Dec. 31, 2013
Details
Proceeds from related party notes payable	$5,000	[1]	$25,000	[1]	$30,000
[1]	In April 2013, the balance on the note was repaid in full.

Note_6_Derivative_Liability_an1

Note 6 - Derivative Liability and Fair Value Measurements (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Details
Gain (loss) on derivative liability	$0	($3,926)

Note_7_Preferred_Stock_Details

Note 7 - Preferred Stock (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Preferred Stock Authorized	5,000,000
Preferred Stock Par Value	$0.10
Series A Preferred Stock
Preferred Stock Authorized	5,000	5,000
Preferred Stock Par Value	$0.10	$0.10
Preferred Stock Issued	3,256	3,256
Series B Preferred Stock
Preferred Stock Authorized	3,000	3,000
Preferred Stock Par Value	$0.10	$0.10
Preferred Stock Issued	2,146	2,146
Series C Preferred Stock
Preferred Stock Authorized	6,000	6,000
Preferred Stock Par Value	$0.10	$0.10
Preferred Stock Issued	5,001	5,001
Series D Preferred Stock
Preferred Stock Authorized	6,000	6,000
Preferred Stock Par Value	$0.10	$0.10
Preferred Stock Issued	320	320

Note_8_Common_Stock_Details

Note 8 - Common Stock (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Common stock issued for services	$34,000	$34,000
Common Stock
Common stock issued for services - shares	40,000	40,000
Common stock issued for services	-40	-40
Common stock issued for payment of preferred stock dividends	1,206
Common stock issued for payment of preferred stock dividends - shares	1,206,387
Additional Paid in Capital
Common stock issued for services	-33,960	-33,960
Common stock issued for payment of preferred stock dividends	$1,024,198

Note_9_Warrants_Schedule_of_St1

Note 9 - Warrants: Schedule of Stockholders' Equity Note, Warrants or Rights (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Details
Class of Warrant or Right, Outstanding	12,550,062	13,018,764	8,674,372
Warrant Exercise Price	$1.25	$1.07	$1.03
Warrant Weighted Average Grant Date Fair Value	$0.85	$0.85	$0.85
Warrant Expiration date in years	4.6	4.88	2.9
Warrants and Rights Outstanding	$15,699,094	$13,966,350	$8,957,486
Class of Warrant or Right Granted	2,071,011	4,344,392
Warrant Exercise Price Granted	$1.40	$1.15
Warrant Weighted Average Grant Date Fair Value Granted	$0.85	$0.85
Warrant Expiration date in years, granted	4.88	3.7
Warrants And Rights Outstanding, Granted	2,893,701	5,008,864
Class of Warrant or Right Cancelled / Expired	-2,539,713
Warrant Exercise Price Cancelled / Expired	($1.27)
Warrants And Rights Outstanding, Cancelled / Expired	($1,160,957)

Note_9_Warrants_Details

Note 9 - Warrants (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Details
Stock offering costs	$289,240	$550,326
Modification of warrants	$13,132

Note_10_Stock_Options_Schedule1

Note 10 - Stock Options: Schedule of Share-based Compensation, Stock Options (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Details
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	855,000	570,000	100,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$1.06	$0.93	$0.85
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Grant Date Fair Value	$0.85	$0.85	$0.85
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Expiration Date in Years	3.84	4.56	7.5
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Value If Exercised	$907,500	$532,500	$85,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures	285,000	470,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	$1.32	$0.95
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value	$0.85	$0.85
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Granted Expiration Date in Years	5.06	5
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Granted Value If Exercised	$375,000	$447,500

Note_10_Stock_Options_Details

Note 10 - Stock Options (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Amortization of ESOP Award	$217,444	$667,449
StockOptions1Member
Options issued		240,000
Black-Scholes option pricing model assumptions		$0.85 stock price, $.85 and $1.25 exercise prices, 5 years to maturity, 649% volatility, .35% risk free rate.
StockOptions2Member
Options issued		30,000
Black-Scholes option pricing model assumptions		$0.85 stock price, $0.85 exercise price, 5 years to maturity, 885% volatility 88% risk free rate.
StockOptions3Member
Options issued	60,000
Black-Scholes option pricing model assumptions	$0.85 stock price, $1.25 exercise price, 2.69 years to maturity, 305% volatility, .64% risk free rate.
Stock Options 4
Options issued	225,000
Black-Scholes option pricing model assumptions	$0.85 stock price, $1.25 to $2.00 exercise price, 5 years to maturity, 286.96% to 415.87% volatility, 1.66% to 1.92% risk free rate.

Note_11_Income_Taxes_Details

Note 11 - Income Taxes (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Details
Provision for income taxes
Marginal tax rate	39.00%
State And Federal Operating Loss Carryforwards, Net	$9,605,038

Note_11_Income_Taxes_Schedule_2

Note 11 - Income Taxes: Schedule of Deferred Tax Assets and Liabilities (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Details
Operating Loss Carryforwards	$10,171,765	$7,436,707
Deferred Tax Assets, Operating Loss Carryforwards	3,966,988	2,900,316
Operating Loss Carryforwards, Valuation Allowance	($3,966,988)	($2,900,316)

Note_11_Income_Taxes_Schedule_3

Note 11 - Income Taxes: Schedule of Effective Income Tax Rate Reconciliation (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Details
Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount	($1,071,794)	($763,180)
Share-based Compensation		273,565
Derivative liability Income tax		1,531
Modification of Warrants Related to Income Tax Provision	5,121
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount	$1,066,673	$488,084

Note_12_Related_Party_Transact1

Note 12 - Related Party Transactions (Details) (USD $)	1 Months Ended				12 Months Ended
	Mar. 31, 2013		Jan. 31, 2013		Dec. 31, 2013
Details
Proceeds from related party notes payable	$5,000	[1]	$25,000	[1]	$30,000
Repayment of related party notes payable					$30,000
[1]	In April 2013, the balance on the note was repaid in full.

Note_13_Commitment_and_Conting1

Note 13 - Commitment and Contingencies (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 12, 2014
Minimum Annual Royalty	$75,000
Options to Purchase Shares of Common Stock		300,000
Cash Bonus		75,000
JHU License Agreement
License Fees Paid	50,000
License Fees within one year	10,000
License Fees year three	25,000
License Fees year four	25,000
License Fees year five and onward	30,000
Aggregate License Fees Paid	160,000
2013 Agreement
License Fees within one year	15,000
License Fees year three	10,000
License Fees year four	20,000
License Fees year five and onward	30,000
License Fees upon signing	$10,000